MEDI0457 clinical trials
Also written INO-3112 and MEDI0457.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses MEDI0457 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 3
Inovio Pharmaceuticals (2) · MedImmune LLC (1) · M.D. Anderson Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses MEDI0457 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated CancersTerminatedPhase 2M.D. Anderson Cancer CenterNCT03439085Written as DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
- Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerCompletedPhase 1/2MedImmune LLCNCT03162224Written as MEDI0457
- Therapy for High-Risk HPV 16-Positive Oropharynx Cancer PatientsWithdrawnPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04001413Written as MEDI0457
- A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical CancerCompletedPhase 1/2Inovio PharmaceuticalsNCT02172911Written as INO-3112
- Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell CarcinomaCompletedPhase 1/2Inovio PharmaceuticalsNCT02163057Written as INO-3112
- A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical CancerWithdrawnPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT02501278Written as INO-3112 vaccine